Literature DB >> 12580542

Inflammation in the central nervous system: the role for dendritic cells.

Mikhail Pashenkov1, Natalia Teleshova, Hans Link.   

Abstract

Dendritic cells (DCs) are a subclass of antigen-presenting cells critical in the initiation and regulation of adaptive immunity against pathogens and tumors, as well as in the triggering of autoimmunity. Recent studies have provided important knowledge regarding distribution of DCs in the central nervous system (CNS) and their role in intrathecal immune responses. DCs are present in normal meninges, choroid plexus, and cerebrospinal fluid, but absent from the normal brain parenchyma. Inflammation is accompanied by recruitment and/or development of DCs in the affected brain tissue. DCs present in different compartments of the CNS are likely to play a role in the defence against CNS infections, and also may contribute to relapses/chronicity of CNS inflammation and to break-down of tolerance to CNS autoantigens. CNS DCs can therefore be viewed as a future therapeutic target in chronic inflammatory diseases such as multiple sclerosis.

Entities:  

Mesh:

Year:  2003        PMID: 12580542     DOI: 10.1111/j.1750-3639.2003.tb00003.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  19 in total

Review 1.  Multiple sclerosis: new insights and trends.

Authors:  M Inglese
Journal:  AJNR Am J Neuroradiol       Date:  2006-05       Impact factor: 3.825

Review 2.  Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions.

Authors:  Pedro R Lowenstein; Ronald J Mandel; Wei-Dong Xiong; Kurt Kroeger; Maria G Castro
Journal:  Curr Gene Ther       Date:  2007-10       Impact factor: 4.391

3.  Preliminary evidence of the in vitro effects of BDE-47 on innate immune responses in children with autism spectrum disorders.

Authors:  Paul Ashwood; Joseph Schauer; Isaac N Pessah; Judy Van de Water
Journal:  J Neuroimmunol       Date:  2009-02-10       Impact factor: 3.478

4.  Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis.

Authors:  A Sanna; M L Fois; G Arru; Y-M Huang; H Link; M Pugliatti; G Rosati; S Sotgiu
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

5.  Immune cell trafficking from the brain maintains CNS immune tolerance.

Authors:  Mohammad G Mohammad; Vicky W W Tsai; Marc J Ruitenberg; Masoud Hassanpour; Hui Li; Prue H Hart; Samuel N Breit; Paul E Sawchenko; David A Brown
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

6.  Comparing the Immune-Genomic Effects of Vilazodone and Paroxetine in Late-Life Depression: A Pilot Study.

Authors:  Harris Eyre; Prabha Siddarth; Natalie Cyr; Hongyu Yang; Steve Cole; Malcolm Forbes; Helen Lavretsky
Journal:  Pharmacopsychiatry       Date:  2017-04-25       Impact factor: 5.788

Review 7.  The importance of NAD in multiple sclerosis.

Authors:  W Todd Penberthy; Ikuo Tsunoda
Journal:  Curr Pharm Des       Date:  2009       Impact factor: 3.116

8.  Flt3L in combination with HSV1-TK-mediated gene therapy reverses brain tumor-induced behavioral deficits.

Authors:  Gwendalyn D King; Kurt M Kroeger; Catherine J Bresee; Marianela Candolfi; Chunyan Liu; Charlene M Manalo; A K M Ghulam Muhammad; Robert N Pechnick; Pedro R Lowenstein; Maria G Castro
Journal:  Mol Ther       Date:  2008-02-19       Impact factor: 11.454

Review 9.  Cysteine cathepsins in neurological disorders.

Authors:  Anja Pišlar; Janko Kos
Journal:  Mol Neurobiol       Date:  2013-11-15       Impact factor: 5.590

Review 10.  Immunology of neurological gene therapy: how T cells modulate viral vector-mediated therapeutic transgene expression through immunological synapses.

Authors:  Pedro R Lowenstein; Kurt Kroeger; Maria G Castro
Journal:  Neurotherapeutics       Date:  2007-10       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.